The present investigation was undertaken to determine the clinical relevance of using a combination of multiple deregulated oncogenic products, including EGFR, the phosphorylated form of Akt, NF-κB p65 and MIC-1 as molecular biomarkers to predict the risk of PC progression to locally advanced tumor and therapeutic targets to eradicate the total PC cell mass. Here, EGFR is linked to pachyonychia congenita.